Youcare Pharmaceutical (SH:688658) Zhi Tong Cai Jing·2025-11-27 08:10Core Viewpoint - YKYY018 aerosol inhalation agent developed by the company has received FDA approval for clinical trials aimed at preventing and treating respiratory syncytial virus (RSV) infections [1] Company Summary - The company’s wholly-owned subsidiary, Beijing YKANG Kechuang Pharmaceutical Technology Co., Ltd., has obtained the FDA's Study May Proceed Letter for YKYY018 [1] - YKYY018 is an internationally original membrane fusion inhibitor drug developed using the company's AI platform, specifically targeting RSV infections [1] - The product has a novel mechanism of action, binding specifically to the HR1 region of the F protein of RSV, inhibiting the formation of the 6-HB structure, and blocking the fusion process between the virus and host cells [1] - The company holds core patent rights for YKYY018 and possesses global exclusive rights to the product [1]